News Conference News ESC 2025 Mixed Results for Beta-blockers in Post-MI Patients With Preserved EF Michael O'Riordan August 30, 2025
News Conference News AHA 2024 Spironolactone No Help for the Heart After Acute MI: CLEAR SYNERGY Shelley Wood November 17, 2024
News Conference News ESC 2024 Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD Todd Neale September 01, 2024
News Conference News AHA 2023 DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI Shelley Wood November 11, 2023
News Conference News HFSA 2023 Semaglutide Works Across LVEF Range: STEP-HFpEF Analysis Todd Neale October 11, 2023
News Conference News ESC 2023 ESC Focused Update on HF Synthesizes New Trial Data for Practical Use L.A. McKeown September 01, 2023
News Conference News ESC 2023 New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground Caitlin E. Cox August 30, 2023
News Conference News ESC 2022 PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2 Michael O'Riordan August 27, 2022
News Conference News ESC Heart Failure 2019 Rivaroxaban Cuts Major Stroke Risk in COMMANDER HF Post Hoc Analysis Shelley Wood May 26, 2019
News Conference News ACC 2019 New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin Shelley Wood March 26, 2019
News Conference News CRT 2019 Rivaroxaban in Addition to DAPT Lowers Death, MI, Stroke in ACS, Heart Failure Patients: Meta-analysis Yael L. Maxwell March 03, 2019
News Conference News ESC 2018 COMMANDER HF: Low-Dose Rivaroxaban Flops in Heart Failure Todd Neale August 27, 2018